+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hepatoprotection in ethinylestradiol-treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid



Hepatoprotection in ethinylestradiol-treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid



Journal Of Gastroenterology & Hepatology. 10(3): 261-269



Ursodeoxycholic acid (UDCA) and tauroursodeoxycholic acid (TUDCA) have been suggested as potential treatments for drug-induced cholestasis. It was therefore decided to study the effects of administration of UDCA or TUDCA on individual serum bile acid concentrations, conventional liver tests and associated hepatic ultrastructural changes in ethinylestradiol-treated (EE) rats (5 mg/kg per day). Control rats were treated s.c. with propylene glycol. EE-treated rats were randomly assigned to receive daily i.p. injections of placebo, TUDCA or UDCA. Four rats in each group were treated for 4 consecutive days, and a second four for 14 days. After 4 days of treatment, the serum levels of cholic acid and taurocholic acid were significantly increased in EE-treated rats. None of the conventional liver tests were significantly different among the four groups. After 14 days of treatment the serum levels of cholic acid, chenodeoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, bilirubin, alkaline phosphatase and gamma glutamyltransferase were significantly raised in EE and EE plus UDCA treated rats. EE plus TUDCA treated rats, however, had no significant changes in these individual serum bile acids or conventional liver tests. The ultrastructure of livers from EE plus TUDCA treated rats was similar to those of controls. On the other hand, EE and EE plus UDCA rats both showed a significant reduction in sinusoidal microvilli. These results show that treatment of rats for 4 days with EE induces significant rises in the serum concentrations of two individual bile acids and that TUDCA protects against this. On treatment over 14 days TUDCA provides protection against changes in several biochemical liver tests as well as ultrastructural hepatoprotection. Treatment with UDCA, however, afforded no such protection.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008766511

Download citation: RISBibTeXText

PMID: 7548801

DOI: 10.1111/j.1440-1746.1995.tb01091.x


Related references

Hepatoprotection in ethynylestradiol-treated rats in provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid. Hepatology 18(4 PART 2): 311A, 1993

Ursodeoxycholic acid and tauroursodeoxycholic acid suppress choroidal neovascularization in a laser-treated rat model. Journal of Ocular Pharmacology and Therapeutics 26(3): 223-229, 2010

Ursodeoxycholic acid and not tauroursodeoxycholic acid prevents the ethynylestradiol induced intrahepatic cholestasis in rats. Gastroenterology 98(5 PART 2): A651, 1990

Chronic administration of ursodeoxycholic and tauroursodeoxycholic acid changes microsomal membrane lipid content and fatty acid composition in rats. Biochemical & Biophysical Research Communications. 220(3): 479-483, 1996

Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid. Biochimica et Biophysica Acta 1644(1): 37-45, 2004

Neither ursodeoxycholic acid nor tauroursodeoxycholic acid protects rabbit hepatocytes from toxic bile acids. Gastroenterology 98(5 PART 2): A600, 1990

Ursodeoxycholic acid versus tauroursodeoxycholic acid Crossover study of their absorption and biliary enrichment in man. Hepatology 24(4 PART 2): 372A, 1996

Tauroursodeoxycholic acid, ursodeoxycholic acid and gallbladder motility in gallstone patients and healthy subjects. Italian Journal of Gastroenterology 28(2): 111-113, 1996

Ursodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytes. Plos One 8(12): E82086, 2014

Pentoxifylline, but not ursodeoxycholic acid or tauroursodeoxycholic acid inhibits the proliferative effect of sera samples from primary biliary cirrhosis patients. Hepatology Research 7(2): 94-104, 1997

D22-ursodeoxycholic acid, a unique metabolite of administered ursodeoxycholic acid in rats, indicating partial b-oxidation as a major pathway for bile acid metabolism. Biochemistry (American Chemical Society) 34: 69-78, 1995

DELTA-22-ursodeoxycholic acid, a unique metabolite of administered ursodeoxycholic acid in rats, indicating partial beta-oxidation as a major pathway for bile acid metabolism. Biochemistry. 34(13): 4169-4178, 1995

Clinical evidence of hepatoprotection induced by ursodeoxycholic acid. Acta Physiologica Hungarica 80(1-4): 369-374, 1992

Mechanisms of cell injury and death in cholestasis and hepatoprotection by ursodeoxycholic acid. Journal of Hepatology 32(Supplement 2): 11-13, 2000

Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis. Advances in Medical Sciences 51: 54-59, 2007